[go: up one dir, main page]

RU2017136720A - Средство для лечения фиброза почек - Google Patents

Средство для лечения фиброза почек Download PDF

Info

Publication number
RU2017136720A
RU2017136720A RU2017136720A RU2017136720A RU2017136720A RU 2017136720 A RU2017136720 A RU 2017136720A RU 2017136720 A RU2017136720 A RU 2017136720A RU 2017136720 A RU2017136720 A RU 2017136720A RU 2017136720 A RU2017136720 A RU 2017136720A
Authority
RU
Russia
Prior art keywords
extracellular matrix
kidney
activity
growth
pharmaceutical composition
Prior art date
Application number
RU2017136720A
Other languages
English (en)
Other versions
RU2017136720A3 (ru
RU2711531C2 (ru
Inventor
Еширо НИИТСУ
Кейко КАДЖИВАРА
Ясунобу ТАНАКА
Мийоно МИЯЗАКИ
Original Assignee
Нитто Денко Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нитто Денко Корпорейшн filed Critical Нитто Денко Корпорейшн
Publication of RU2017136720A3 publication Critical patent/RU2017136720A3/ru
Publication of RU2017136720A publication Critical patent/RU2017136720A/ru
Application granted granted Critical
Publication of RU2711531C2 publication Critical patent/RU2711531C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (9)

1. Носитель для in vivo доставки вещества в продуцирующие внеклеточный матрикс клетки в почке, причем носитель состоит из липидной структуры, содержащей ретиноид в качестве компонента, способствующего доставке вещества в продуцирующие внеклеточный матрикс клетки в почке, где носитель имеет форму липосомы, и где вещество представляет собой лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке.
2. Носитель по п. 1, в котором ретиноид содержит ретинол.
3. Фармацевтическая композиция для лечения фиброза почек, отличающаяся тем, что она содержит носитель по п. 1 и лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке.
4. Фармацевтическая композиция по п. 3, в которой мольное отношение ретиноида и липида, содержавшегося в липосоме, составляет от 8:1 до 1:4.
5. Фармацевтическая композиция по п. 3, в которой лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке выбирается из группы, состоящей из ингибитора активности или продуцирования PAI-1, ингибитора клеточной активности, ингибитора роста, индуктора апоптоза и молекулы РНКи, рибозима, антисмысловой нуклеиновой кислоты или ДНК/РНК химерного полинуклеотида, которые нацелены по меньшей мере на одно из молекул, составляющих внеклеточный матрикс, или молекул, вовлеченных в продуцирование, или секреции молекул, составляющих внеклеточный матрикс, или вектора, экспрессирующего их.
6. Фармацевтическая композиция по п. 3, в которой лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток представляет собой ингибитор HSP47.
7. Фармацевтическая композиция по любому из пп. 3-5, в которой лекарственное средство и носитель смешиваются в месте лечения или поблизости от него.
8. Набор для получения фармацевтической композиции по любому из пп. 3-7, отличающийся тем, что он содержит один или более контейнеров, которые содержат либо по отдельности, либо в комбинации лекарственное средство для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке и носитель по п. 1.
9. Способ получения фармацевтической композиции по любому из пп. 3-7, отличающийся тем, что он содержит стадию составления смеси ретиноида в качестве компонента, способствующего доставке лекарственного средства в продуцирующие внеклеточный матрикс клетки в почке, и лекарственного средства для контроля активности или роста продуцирующих внеклеточный матрикс клеток в почке в качестве активного ингредиента.
RU2017136720A 2010-06-17 2011-06-17 Средство для лечения фиброза почек RU2711531C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-138070 2010-06-17
JP2010138070 2010-06-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013101969A Division RU2635460C2 (ru) 2010-06-17 2011-06-17 Средство для лечения фиброза почек

Publications (3)

Publication Number Publication Date
RU2017136720A3 RU2017136720A3 (ru) 2019-02-08
RU2017136720A true RU2017136720A (ru) 2019-02-08
RU2711531C2 RU2711531C2 (ru) 2020-01-17

Family

ID=45348325

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017136720A RU2711531C2 (ru) 2010-06-17 2011-06-17 Средство для лечения фиброза почек
RU2013101969A RU2635460C2 (ru) 2010-06-17 2011-06-17 Средство для лечения фиброза почек

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013101969A RU2635460C2 (ru) 2010-06-17 2011-06-17 Средство для лечения фиброза почек

Country Status (12)

Country Link
US (2) US20130136789A1 (ru)
EP (1) EP2583691B1 (ru)
JP (2) JP2012020995A (ru)
KR (1) KR101967868B1 (ru)
CN (1) CN102933233A (ru)
AU (1) AU2011266057B2 (ru)
CA (1) CA2802414C (ru)
ES (1) ES2712086T3 (ru)
IN (1) IN2013CN00342A (ru)
RU (2) RU2711531C2 (ru)
TW (1) TWI549691B (ru)
WO (1) WO2011158933A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
CA2935334C (en) * 2013-01-18 2021-05-25 Cornell University Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists
EP3127915B1 (en) 2014-04-02 2020-08-26 Nitto Denko Corporation Rbp-derived targeting molecule and utilization thereof
EP3129425B1 (en) 2014-04-07 2019-04-10 Nitto Denko Corporation Polymer-based hydrotropes for hydrophobic drug delivery
CN105597085A (zh) * 2015-12-17 2016-05-25 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21在治疗肾纤维化中的应用
JP6833456B2 (ja) * 2016-11-02 2021-02-24 日東電工株式会社 皮膚線維症処置剤
KR102352489B1 (ko) 2019-12-09 2022-01-18 전남대학교산학협력단 소수성 개질된 글리콜 키토산 나노입자 및 이를 이용한 신장 표적화 약물 전달체

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238924A (en) 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6334999B1 (en) * 1999-08-27 2002-01-01 Research Development Foundation Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs
ES2263557T3 (es) 2000-01-31 2006-12-16 Pfizer Products Inc. Uso de agonistas selectivos del receptor 4(ep4) de prostablandinas (pge2) para el tratamiento de insuficiencia renal aguda y cronica.
BR0006556A (pt) * 2000-12-28 2002-09-17 Apsen Farmaceutica S A Composição farmacêutica para uso tópico à base de corticosteróide para tratamento de fimose
IL143366A0 (en) 2001-05-24 2002-04-21 Harasit Medical Res Services & Treatment of renal fibrosis
JP2004043459A (ja) 2002-05-24 2004-02-12 Sumitomo Pharmaceut Co Ltd ＴＧＦ−β阻害活性を有する低分子化合物からなる医薬
EP1454625A1 (en) 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
US7396825B2 (en) 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
KR100613342B1 (ko) 2004-12-16 2006-08-21 동부일렉트로닉스 주식회사 반도체 소자 및 그 제조방법
DK2727583T3 (da) 2004-12-22 2021-12-20 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til at inhibere fibrose
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
JP2007099641A (ja) 2005-09-30 2007-04-19 Tsumura & Co インドールキノキサリン類化合物、その製造方法およびそれを用いた医薬組成物
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
JP2009292725A (ja) 2006-09-01 2009-12-17 Stelic Institute Of Regenerative Medicine 腎疾患改善剤
TWI407971B (zh) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
JP2009007258A (ja) 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd Ｐａｉ−１産生抑制作用を有する３−アニリノ−２−シクロアルケノン誘導体
JP2009029750A (ja) 2007-07-27 2009-02-12 Kowa Co アリールプロパン誘導体を有効成分とする糖化最終産物形成阻害剤
EP2207570A2 (en) * 2007-09-14 2010-07-21 Nitto Denko Corporation Drug carriers
JP2009178143A (ja) 2008-02-01 2009-08-13 Stelic Institute Of Regenerative Medicine 脂肪性肝炎−肝癌モデル動物
EP2323693B1 (en) * 2008-07-30 2017-11-08 Nitto Denko Corporation Drug carriers
KR20160095209A (ko) * 2008-09-12 2016-08-10 닛토덴코 가부시키가이샤 섬유증 질환의 조영제
JP2010077101A (ja) 2008-09-29 2010-04-08 Toray Ind Inc 腎線維症の治療剤又は予防剤
PT2509991E (pt) * 2009-12-09 2016-01-12 Nitto Denko Corp Modulação da expressão de hsp47
RU2769872C2 (ru) * 2011-06-08 2022-04-07 Нитто Денко Корпорейшн СОЕДИНЕНИЯ ДЛЯ НАЦЕЛЕННОЙ ДОСТАВКИ ЛЕКАРСТВЕННОГО СРЕДСТВА И УСИЛЕНИЯ АКТИВНОСТИ siPHK

Also Published As

Publication number Publication date
CA2802414C (en) 2018-01-09
RU2635460C2 (ru) 2017-11-13
KR20130121813A (ko) 2013-11-06
RU2017136720A3 (ru) 2019-02-08
EP2583691A1 (en) 2013-04-24
TWI549691B (zh) 2016-09-21
IN2013CN00342A (ru) 2015-07-03
JP2015155459A (ja) 2015-08-27
US20130136789A1 (en) 2013-05-30
JP2012020995A (ja) 2012-02-02
JP5873589B2 (ja) 2016-03-01
EP2583691B1 (en) 2019-01-16
KR101967868B1 (ko) 2019-08-19
RU2711531C2 (ru) 2020-01-17
TW201204389A (en) 2012-02-01
AU2011266057B2 (en) 2014-12-04
RU2013101969A (ru) 2014-07-27
US20150259683A1 (en) 2015-09-17
EP2583691A4 (en) 2016-04-27
ES2712086T3 (es) 2019-05-09
WO2011158933A1 (ja) 2011-12-22
AU2011266057A1 (en) 2013-01-10
CN102933233A (zh) 2013-02-13
CA2802414A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
RU2017136720A (ru) Средство для лечения фиброза почек
RU2015105524A (ru) Терапевтический агент, применяемый при пневмофиброзе
Grijalvo et al. Cationic niosomes as non-viral vehicles for nucleic acids: Challenges and opportunities in gene delivery
Bure et al. Histone modifications and non-coding RNAs: mutual epigenetic regulation and role in pathogenesis
Seyhan Trials and tribulations of MicroRNA therapeutics
Lavenniah et al. Engineered circular RNA sponges act as miRNA inhibitors to attenuate pressure overload-induced cardiac hypertrophy
Landmesser et al. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Sadakierska-Chudy MicroRNAs: diverse mechanisms of action and their potential applications as cancer epi-therapeutics
Islas et al. A microRNA perspective on cardiovascular development and diseases: an update
Costa et al. MicroRNAs as molecular targets for cancer therapy: on the modulation of microRNA expression
Levingstone et al. Calcium phosphate nanoparticles-based systems for RNAi delivery: Applications in bone tissue regeneration
WO2012170957A8 (en) Retinoid-liposomes for enhancing modulation of hsp47 expression
RU2011112645A (ru) Средство для лечения миелофиброза
RU2014101547A (ru) Апоптоз-индуцирующее средство
Grieco et al. Targeting microRNAs as a therapeutic strategy to reduce oxidative stress in diabetes
EP4249036A3 (en) Methods and products for nucleic acid production and delivery
Nappi Non-coding RNA-targeted therapy: a state-of-the-art review
Adamcova et al. The impact of microRNAs in renin–angiotensin-system-induced cardiac remodelling
Zhu et al. RNA-targeted therapies and high-throughput screening methods
WO2013096958A8 (en) Compositions and methods for the delivery of biologically active rnas
Alvarez et al. Towards microRNA-based therapeutics for diabetic nephropathy
Ma et al. I-motif-based in situ bipedal hybridization chain reaction for specific activatable imaging and enhanced delivery of antisense oligonucleotides
van der Ven et al. In vitro 3D model and miRNA drug delivery to target calcific aortic valve disease
Wong et al. Potential miRNAs for miRNA-based therapeutics in breast cancer
Wu et al. Induction of osteogenic differentiation of stem cells via a lyophilized microRNA reverse transfection formulation on a tissue culture plate